 Clinical Oncology News | Clinical Conundrums Clinical Oncology News True or False: The preliminary results of the open-label Phase II GAUSS trial of rituximab (Rituxan; Biogen Idec, Genentech) versus obinutuzumab (GA101, Roche) for relapsed follicular lymphoma (FL) demonstrated better ORR with induction obinutuzumab ... |
